Clinical trials: Relapse Management, open to volunteers
Non Hodgkin Lymphoma, Richter Transformation
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing…
- Conditions
- Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia
- Trial name
- NCT04771572
- Testing
- LP-118
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Newave Pharmaceutical Inc
Heart-Assist Devices, Infections
Complications in Pediatric Mechanical Circulatory Assistance: Evaluation of Infection Management.
Heart failure is a major cause of mortality and morbidity in children. Heart transplantation can significantly improve the prognosis of patients with severe heart failure, but access is limited by a shortage of transplants.
- Conditions
- Heart-Assist Devices, Infections, Heart Transplant Infection
- Trial name
- VADINFECT (NCT06464016)
- Testing
- Ventricular Assist Device with Berlin Heart EXCOR
- Where
- France
- Volunteers
- 47 people
- Sponsor
- Claude Bernard University
Acute Leukemia, Relapsed or Refractory Pediatric Leukemia
Menin Inhibitors in Pediatric Relapsed or Refractory Acute Leukemia
Acute leukemia is the most common childhood cancer. Despite advances in targeted therapies and immunotherapies, treatment remains challenging for children with relapsed or refractory acute leukemia, particularly those with KMT2A…
- Conditions
- Acute Leukemia, Relapsed or Refractory Pediatric Leukemia, KMT2A-rearranged, NUP98-rearranged, or NPM1-mutated Leukemia, Menin Inhibitor Treatment
- Trial name
- MENIN-PED (NCT07898436)
- Where
- France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Strasbourg, France
B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma
Co-administration of CART22-65s and huCART19 for B-ALL
This study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymphoblastic Leukemia (B-ALL).
- Trial name
- NCT05674175
- Testing
- Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s), Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Stephan Grupp MD PhD
Hodgkin's Disease, Non-Hodgkin's Lymphoma
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
Subjects have a type of lymph gland disease called Hodgkin or non-Hodgkin Lymphoma or T/NK-lymphoproliferative disease or severe chronic active Epstein Barr Virus (CAEBV) which has come back, is at risk of coming back, or has not…
- Conditions
- Hodgkin's Disease, Non-Hodgkin's Lymphoma, Lymphoproliferative Disease, Lymphoma
- Trial name
- GRALE (NCT01555892)
- Testing
- EBV-specific T cells: A, EBV-specific T cells: B
- Where
- 3 sites in United States
- Volunteers
- 136 people
- Sponsor
- Baylor College of Medicine
Immune Thrombocytopenia, Treatment
Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
This randomized, open-label study aim to compare the efficacy and safety of Daratumumab (anti-CD38 monoclonal antibody) with Rituximab in pediatric ITP patients.This study will be conducted in pediatric ITP patients who had not…
- Trial name
- NCT07362238
- Testing
- Rituximab, Daratumumab
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Neuroblastoma, Neuroblastoma Recurrent
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
This research is being done to investigate a treatment regimen of Irinotecan, Temozolomide, and Sargramostin, and an immunotherapy called Naxitamab and whether giving Naxitamab more slowly reduces the side effects for…
- Conditions
- Neuroblastoma, Neuroblastoma Recurrent, Relapsed Neuroblastoma, Refractory Neuroblastoma
- Trial name
- NCT07027748
- Testing
- Naxitamab, Irinotecan, Temozolomide
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Steven DuBois, MD
Glioma
Tessa Jowell BRAIN MATRIX - Platform Study
The main aim of the Tessa Jowell BRAIN MATRIX - Platform Study is to more precisely determine the exact type of tumour patients have by developing the essential infrastructure to provide rapid and accurate molecular diagnosis.
- Trial name
- BRAIN MATRIX (NCT04274283)
- Testing
- Matched Tumour and Blood Sample - Research Pathway, Matched Tumour and Blood Sample - NHS GMS pathway
- Where
- 14 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- University of Birmingham
Relapsing-remitting Multiple Sclerosis
A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
The main purpose of this study is to evaluate the pharmacokinetics (PK) of ocrelizumab administered subcutaneously (SC) in children and adolescents aged 10 to <18 years with RRMS.
- Trial name
- Operetta III (NCT07503340)
- Testing
- Ocrelizumab co-formulated with rHuPH20
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche
Denis Brawn Brace, Modification
Original Denis Brawn Brace Versus Its Modification for Management of Relapsed Idiopathic Clubfoot Following Ponseti Casting
This study aims to compare the effectiveness of the original Denis Brawn brace to its modification in managing relapsed idiopathic clubfoot in patients following Ponseti casting.
- Conditions
- Denis Brawn Brace, Modification, Management, Idiopathic Clubfoot
- Trial name
- NCT07125794
- Testing
- Original Denis Browne splint, Modified Denis Browne splint
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- The General Authority for Teaching Hospitals and Institutes
B-Cell Lymphoma, Myelodysplastic Syndromes (MDS)
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma.
- Conditions
- B-Cell Lymphoma, Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), Multiple Myeloma
- Trial name
- NCT05092451
- Testing
- Cyclophosphamide, CAR.70/IL15-transduced CB-NK cells, Fludarabine phosphate
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center